Compugen Ltd. Q4 FY2024 earnings call

COM701: Presented data on triple blockade with PVRIG, TIGIT, and PD-1 showing durable responses and good tolerability. Advancing as maintenance treatment for platinum-sensitive ovarian cancer, with plan to initiate adaptive platform trial in Q2 2025. ### TIGIT Landscape: Fc inactive antibodies may have safety and efficacy advantages. AstraZeneca initiated Phase III trials with rilvegostomig, TIGIT component from Compugen's COM902. ### GS-0321: Licensed to Gilead, received $30M milestone for FDA IND clearance, Phase I trial initiated in early Jan 2025. ### Financials: Solid balance sheet with no debt, cash runway to 2027, revenues include Gilead and AstraZeneca payments.

As of December 31, 2024, cash balance was approximately $103.3 million. Revenues for Q4 2024 were ~$1.5 million, and for the year ~$27.9 million. R&D expenses for Q4 2024 were ~$5.9 million, and for the year ~$24.8 million. G&A expenses for Q4 2024 were ~$2.2 million, and for the year ~$9.4 million. Net loss for Q4 2024 was ~$6.1 million, and for the year ~$14.2 million.

COM701: On track to initiate adaptive platform trial in Q2 2025, with interim analysis expected in H2 2026. ### AstraZeneca: Plans to share early data on rilvegostomig with ADCs in 2025. ### GS-0321: Focus on efficient execution of Phase I trial.

Q: Question on AstraZeneca's Phase III endometrial study for B7-H4DCTSM and inclusion of COM701.

A: Cannot relate to unpublicized info, AstraZeneca moving forward with multiple trials.

Q: Follow-up on near-term data from AstraZeneca on TIGIT contribution.

A: AstraZeneca expected to present data in 2025 on rilvegostomig with ADC.

Q: Follow-up on which Phase III trial from AstraZeneca will read out first.

A: AstraZeneca hasn't shared timeline details.

Q: Question on ovarian study design, PFS hazard ratio, balance.

A: Study is exploratory Phase Ib, uses Bayesian stats, adaptive design.

Q: Follow-up on patient eligibility bias in ovarian study.

A: Stratification by PARP inhibitor use to ensure balance, captures third-line population.

Q: Question on 0321 in hematologic malignancies.

A: Focus on solid tumors now, but hematologic could be interesting.

Q: Question on adaptive nature of ovarian study.

A: Adaptive allows adding arms or increasing sample size based on interim analysis.

Q: Question on enrollment rate in ovarian study.

A: Fast enrollment expected due to few trials for specific population.

Q: Question on interim analysis trigger for ovarian study.

A: Combination of event rate and follow-up, with independent data review committee.

Q: Question on 0321 dose escalation study biopsies and PD data.

A: Certain cohorts will have on-treatment biopsies to assess on-target activity.